TY - JOUR T1 - ELIPSE-COL: A novel ELISA test based on rational envisioned synthetic peptides for detection of SARS-CoV-2 infection in Colombia JF - medRxiv DO - 10.1101/2020.11.13.20230060 SP - 2020.11.13.20230060 AU - Adriana Arévalo AU - Carlos Franco-Muñoz AU - Sofía Duque-Beltrán AU - Lyda Muñoz-Galindo AU - María Herrera-Sepulveda AU - José Manuel Lozano AU - Luz Mary Salazar AU - Martha L. Ospina-Martinez AU - Marcela Mercado-Reyes Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/05/2020.11.13.20230060.abstract N2 - Background COVID-19 pandemic caused by infection with the betacoronavirus SARS-CoV-2 is the greatest public health defiant on a global scale in the last 100 years. Governments and health Institutes face challenges during the pandemic, related to the diagnosis, mitigation, treatment, and timely detection after the epidemic peak for the prevention of new infections and the evaluation of the real impact of the COVID-19 disease in different geographic areas. To develop a valuable tool to study the seroprevalence of SARS-CoV-2 infection in Colombia, an “in-house” ELISA was achieved for the detection of IgG anti-SARS-CoV-2 antibodies in serum.Methods The test was standardized using an antigenic epitope “Pool” of the synthetic peptide as antigen derived from antigenic regions of the spike, nucleocapsid, envelope, and membrane structural proteins, which were designed, based on the genomic information of SARS-CoV-2 circulating in Colombia. In the ELISA standardization process, 94 positive sera were used, including sera from asymptomatic and symptomatic patients (mild and severe) and 123 negative sera, including pre-pandemic historical negatives originating from patients living in arbovirus endemic areas or patients with a history of respiratory diseases and sera from patients with a negative rRT-PCR test for SARS-CoV-2.Results The in-house peptide ELIPSE-COL test showed promising performance, being able to detect reactivity in sera from asymptomatic and symptomatic patients. The sensitivity and specificity of the assay were 91.4% and 83.7% respectively.Conclusion ELIPSE-COL assay was developed as an ELISA test using synthetic peptides for the study of the seroprevalence of SARS-CoV-2 infection in Colombia.SUMMARY BOXDetection of IgG anti-SARS-CoV-2 antibodies is required for the evaluation of the pandemic impact and vaccination strategies.ELIPSE-COL is an in-house test based on synthetic peptides as antigen derived from antigenic regions of the spike, nucleocapsid, envelope, and membrane structural proteins.The sensitivity and specificity of the assay were 91.4% and 83.7% respectively suggesting a promising performance.ELIPSE-COL test is a valuable tool for the study of seroprevalence in Colombia.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Ministerio de Ciencia Tecnologia e Innovacion (MinCiencias) (project number: 2104101577317, contract number: 361-2020) and by the National Institute of Health, Bogota, ColombiaAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was approved by the Ethics and Research Methodologies Committee (CEMIN) of the National Institute of Health (created by resolution 395 of April 4, 2017) who determined that the work meets the technical and ethical requirements for which they granted ethical approval registered in Act No. 7 of April 13, 2020. This work was developed according to the national law 9/1979, decrees 786/1990 and 2323/2006, which establishes that the Instituto Nacional de Salud (INS) from Colombia is the reference laboratory and health authority of the national network of laboratories and in cases of a public health emergency or those in which scientific research for public health purposes as required. This study was performed following the ethical standards of the Declaration of Helsinki 1964 and its later amendments. The information used for this study comes from secondary sources of data that were previously anonymized and do protect patient data. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be available at the final publication ER -